|Active surveillance for clinically localized prostate cancer––A systematic review|
FB Thomsen, K Brasso, LH Klotz, MA Røder, KD Berg, P Iversen
Journal of surgical oncology 109 (8), 830-835, 2014
|ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer|
KD Berg, B Vainer, FB Thomsen, MA Røder, TA Gerds, BG Toft, K Brasso, ...
European urology 66 (5), 851-860, 2014
|Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis|
K Brasso, FB Thomsen, AJ Schrader, SC Schmid, D Lorente, M Retz, ...
European urology 68 (2), 317-324, 2015
|Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate|
FB Thomsen, MA Røder, P Rathenborg, K Brasso, M Borre, P Iversen
Scandinavian journal of urology 48 (3), 268-275, 2014
|Active surveillance can reduce overtreatment in patients with low-risk prostate cancer|
FB Thomsen, MA Røder, H Hvarness, P Iversen, K Brasso
Dan Med J 60 (2), A4575, 2013
|Pulmonary function in patients with germ cell cancer treated with bleomycin, etoposide, and cisplatin|
J Lauritsen, MGG Kier, M Bandak, MS Mortensen, FB Thomsen, ...
Journal of Clinical Oncology 34 (13), 1492-1499, 2016
|Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study|
FB Thomsen, K Brasso, IJ Christensen, JE Johansson, A Angelsen, ...
European journal of cancer 51 (10), 1283-1292, 2015
|Improved survival for patients with de novo metastatic prostate cancer in the last 20 years|
KD Berg, FB Thomsen, MK Mikkelsen, IJ Ingimarsdóttir, RB Hansen, ...
European Journal of Cancer 72, 20-27, 2017
|Prostate‐specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer|
FB Thomsen, IJ Christensen, K Brasso, MA Røder, P Iversen
BJU international 113 (5b), E98-E105, 2014
|Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older|
FB Thomsen, M Bandak, MF Thomsen, J Lauritsen, IJ Christensen, ...
Cancer 120 (1), 43-51, 2014
|Active surveillance for localized prostate cancer: an analysis of patient contacts and utilization of healthcare resources|
FB Thomsen, KD Berg, MA Røder, P Iversen, K Brasso
Scandinavian journal of urology 49 (1), 43-50, 2015
|The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading–a matched‐pair analysis|
KD Berg, FB Thomsen, C Nerstrøm, MA Røder, P Iversen, BG Toft, ...
BJU international 117 (6), 883-889, 2016
|Association of radical local treatment with mortality in men with very high-risk prostate cancer: a semiecologic, nationwide, population-based study|
P Stattin, F Sandin, FB Thomsen, H Garmo, D Robinson, IF Lissbrant, ...
European urology 72 (1), 125-134, 2017
|Prognostic implications of 2005 Gleason grade modification. Population‐based study of biochemical recurrence following radical prostatectomy|
FB Thomsen, Y Folkvaljon, K Brasso, S Loeb, D Robinson, L Egevad, ...
Journal of surgical oncology 114 (6), 664-670, 2016
|Risk of malignant melanoma in men with prostate cancer: Nationwide, population‐based cohort study|
FB Thomsen, Y Folkvaljon, H Garmo, D Robinson, S Loeb, C Ingvar, ...
International journal of cancer 138 (9), 2154-2160, 2016
|Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study|
FB Thomsen, K Brasso, KD Berg, TA Gerds, JE Johansson, A Angelsen, ...
Annals of Oncology 27 (3), 460-466, 2015
|The predictive value of ERG protein expression for development of castration‐resistant prostate cancer in hormone‐naïve advanced prostate cancer treated with primary androgen …|
KD Berg, MA Røder, FB Thomsen, B Vainer, TA Gerds, K Brasso, ...
The Prostate 75 (14), 1499-1509, 2015
|Risk factors associated with positive surgical margins following radical prostatectomy for clinically localized prostate cancer: can nerve-sparing surgery increase the risk?|
MA Røder, FB Thomsen, IJ Christensen, BG Toft, K Brasso, B Vainer, ...
Scandinavian journal of urology 48 (1), 15-20, 2014
|ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer|
KD Berg, K Brasso, FB Thomsen, MA Røder, H Holten-Rossing, BG Toft, ...
Journal of clinical pathology 68 (10), 788-794, 2015
|Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center|
FB Thomsen, MK Mikkelsen, RB Hansen, AH Krug, A Glenthøj, P Stattin, ...
Acta Oncologica 55 (12), 1456-1460, 2016